PharmaBoardroom

Interview with WonJung Choi, President, Dream CIS

South Korea has a much shorter history of clinical trials than many other advanced economies. In your view, what is the potential for South Korea's…

Interview with Marek Polach, Executive Manager, CzechBio, Czech…

Mr. Polach, can you please begin with an introduction to CzechBio and explicate the association’s mission on this market? CzechBio is an…

Interview: Peter Erlbacher, Chief Operations Officer, Spanish…

The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and…

Interview with Arturo Rodriguez Jacob, Director, Infinite…

We understand that Mexico has a lot of advantages for holding clinical trials, including the large population, access to specialized patient…

Interview with Luboš Chadim, General Manager, Astellas Czech…

Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura,…

Interview with Mario Sicilia , CEO, Bomi de Mexico

You took over BOMI as President and CEO only last year. Could you give us a brief background on BOMI Mexico and yourself? BOMI Mexico was founded in…

Interview with Hilde De Jonge, Managing Director, Belgium…

Let us begin by introducing BACHI, its area of focus and scope of activities? BACHI is a fairly young independent association of the consumer…

Interview with Petr Tor, Country Director, Stallergenes Czech…

Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global…

Interview with Timm Pfannenschmidt, Managing Director, Boehringer…

Mr. Pfannenschmidt, you have been working for Boehringer Ingelheim for three decades, outlasting several company chairman and witnessing the birth and…

Mexico: Shaking Up The System

Over ten years ago, the economic concept of the ‘BRIC’ countries- Brazil, Russia, India and China - was formed, and it’s pretty much…

Stengthening Guidelines for Biosimilars in Mexico

Despite being in the Mexican market for over twenty years, biosimilars have never been regulated as a separate entity. They have always been regulated…

Interview with Daniel Boda, President, National Agency for…

Under various former names for over five decades, the Agency has undoubtedly played a key role in setting a regulatory framework for Romania’s…

Tagged with